Stifel Nicolaus reiterated their positive rating on shares of Edwards Lifesciences (NYSE:EW) in a research note published on Thursday morning, The Fly reports.
A number of other research analysts also recently commented on EW. Raymond James increased their price objective on Edwards Lifesciences from $160.00 to $175.00 and gave the company an outperform rating in a report on Thursday. Bank of America downgraded Edwards Lifesciences from a buy rating to a neutral rating in a report on Tuesday, October 2nd. ValuEngine upgraded Edwards Lifesciences from a hold rating to a buy rating in a report on Wednesday, September 19th. Morgan Stanley increased their price objective on Edwards Lifesciences from $150.00 to $157.00 and gave the company an overweight rating in a report on Thursday, October 11th. Finally, SunTrust Banks dropped their price objective on Edwards Lifesciences to $170.00 and set a buy rating on the stock in a report on Friday, August 10th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the company. The company has a consensus rating of Buy and an average price target of $162.85.
NYSE EW traded down $5.48 during trading hours on Thursday, hitting $157.85. 28,068 shares of the company were exchanged, compared to its average volume of 1,278,365. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.31 and a quick ratio of 1.85. Edwards Lifesciences has a 52-week low of $110.68 and a 52-week high of $175.00. The company has a market cap of $32.89 billion, a price-to-earnings ratio of 41.36, a price-to-earnings-growth ratio of 2.07 and a beta of 0.90.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, October 23rd. The medical research company reported $1.07 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.02 by $0.05. Edwards Lifesciences had a return on equity of 30.11% and a net margin of 20.67%. The company had revenue of $906.60 million for the quarter, compared to the consensus estimate of $927.56 million. During the same quarter in the prior year, the business earned $0.84 EPS. Edwards Lifesciences’s revenue was up 10.4% on a year-over-year basis. Equities research analysts anticipate that Edwards Lifesciences will post 4.7 earnings per share for the current fiscal year.
In other Edwards Lifesciences news, Director William J. Phd Link sold 13,578 shares of the stock in a transaction that occurred on Monday, November 19th. The stock was sold at an average price of $149.92, for a total transaction of $2,035,613.76. Following the completion of the sale, the director now directly owns 16,730 shares of the company’s stock, valued at approximately $2,508,161.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael A. Mussallem sold 32,900 shares of the stock in a transaction that occurred on Wednesday, September 12th. The stock was sold at an average price of $144.02, for a total value of $4,738,258.00. Following the sale, the chief executive officer now directly owns 76,026 shares of the company’s stock, valued at $10,949,264.52. The disclosure for this sale can be found here. Over the last three months, insiders sold 183,356 shares of company stock valued at $27,011,207. Insiders own 1.84% of the company’s stock.
A number of institutional investors have recently bought and sold shares of EW. FMR LLC lifted its holdings in shares of Edwards Lifesciences by 32.9% in the 2nd quarter. FMR LLC now owns 6,714,684 shares of the medical research company’s stock valued at $977,456,000 after buying an additional 1,663,511 shares during the period. Brown Advisory Inc. lifted its holdings in shares of Edwards Lifesciences by 2.2% in the 3rd quarter. Brown Advisory Inc. now owns 3,950,371 shares of the medical research company’s stock valued at $687,760,000 after buying an additional 84,355 shares during the period. Capital Research Global Investors lifted its holdings in shares of Edwards Lifesciences by 164.8% in the 3rd quarter. Capital Research Global Investors now owns 3,545,266 shares of the medical research company’s stock valued at $617,231,000 after buying an additional 2,206,539 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Edwards Lifesciences by 117.0% in the 3rd quarter. Janus Henderson Group PLC now owns 2,505,128 shares of the medical research company’s stock valued at $436,144,000 after buying an additional 1,350,879 shares during the period. Finally, Disciplined Growth Investors Inc. MN lifted its holdings in shares of Edwards Lifesciences by 1.8% in the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 2,063,704 shares of the medical research company’s stock valued at $359,291,000 after buying an additional 36,418 shares during the period. 82.55% of the stock is owned by institutional investors.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
Featured Article: Stock Split
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.